Programme

BioSciPersonalPlanner

The programme is available to download.

Download Programme (pdf) (1.34mb)

Posters >>

Mon 15 March
 09:00 11:00    Registration
     
 11:00 13:00    New Modalities of Treatment in Type 2 Diabetes
Generously supported by Novo Nordisk
Charter A
Chair: M Evans (Cardiff)
11:00 Welcome
M Evans (Cardiff )
11:05 Incretin physiology and rationale for drug development
C Mathieu (Leuven, Belgium)
11:25 Clinical outcome with a once-daily human GLP-1 analogue
M Evans (Cambridge )
11:50 Long-term tight glycaemic control with modern insulins: The 4T study
R Holt (Southampton)
     
 11:00 13:00    Vaptans - A new therapy in action
Generously supported by Otsuka
Charter 3
Chair: J Wass (Oxford)
11:00 Chairman opening: Hyponatraemia syndrome of an inappropriate antidiuresis (SIADH) - common, often misunderstood and mismanaged
J Wass (Oxford)
11:15 Tolvaptan a novel molecule for hyponatraemia due to SIADH: Theory and clinical practice
J Verbalis (Washington, USA)
12:00 SIADH - challenging treatment paradigm: Patient case studies
S Ball (Newcastle Upon Tyne)
     
 13:00 15:00    Symposium1: Novel Mechanistic Insights into Thyroid Diseases
Exchange Auditorium
Chairs: S Pearce (Newcastle) & K Boelaert (Birmingham)
13:00 S1.1 Human mutations causing hypothyroidism
J Moreno (Spain)
13:30 S1.2 Genetic mechanisms defining the response to thyroid hormone replacement
V Panicker (Bristol)
14:00 S1.3 Abnormalities of iodine transport - the clinical spectrum of Pendred's
P Kopp (Chicago, USA)
14:30 S1.4 Novel mechanisms regulating the sodium iodide symporter - implications for thyroid tumorigensis
C McCabe (Birmingham)
     
 13:00 15:00    Clinical Management Workshop 1: Long Term Consequences of Endocrine Diseases
Charter 3
Chairs: V Popovic (Serbia) & H Simpson (Cambridge)
13:00 CM1.1 Subclinical thyroid disease
J Franklyn (Birmingham )
13:10 CM1.2 Mild hyperparathyroidism
P Selby (Manchester)
14:00 CM1.3 Cushing's syndrom
S Webb (Barcelona, Spain)
14:30 CM1.4 Addison's disease
E Husebye (Bergen, Norway)
     
 13:00 15:00    Applied Physiology Workshop: Advances in Endocrine Imaging
Charter A
Chairs: M Gurnell (Cambridge) & J Tomlinson (Birmingham)
13:00 Functional MRI - novel insights into central endocrine regulatory pathways
S Farooqi (Cambridge)
13:30 Recent advances in radionuclide endocrine imaging
S Clarke (London )
14:00 Thyroid ultrasonography - distinguishing benign from malignent lesions
R Evans (Swansea)
14:30 MRI thermometry for the guidance of thermotherapies
B Quesson (Bordeaux, France)
     
 15:00 15:30    Tea & Coffee
Central Hall1
     
 15:30 17:30    Symposium 2: New Endocrinology of Bone
Exchange Auditorium
Chairs: P Selby (Manchester) & S Orme (Leeds)
15:30 S2.1 Insight into bone metabolism from human experiments of nature
M Helfrich (Aberdeen)
16:00 S2.2 PPARgamma osteoporosis and diabetes
C Rosen (Scarborough, ME, USA)
16:30 S2.3 WNT signalling, osteoblasts and bone mass
JP Van Leeuwen (Rotterdam, Netherlands)
17:00 S2.4 FGF23, osteoblasts and phosphate homeostasis
W Fraser (Liverpool)
     
 15:30 17:30    Oral Communications 1: Diabetes and metabolism
Charter 3
Chairs: S Farooqi & B Kola
15:30 OC1.1 IGF-1 receptor and insulin receptor stoichiometry is a critical determinant of nitric oxide bioavailability
A Abbas; H Viswambharan; H Imrie; A Rajwani; S Wheatcroft; P Grant; M Kearney;
15:45 OC1.2 Moderate maternal undernutrition results in the epigenetic changes in the fetal hypothalmic feeding centres, but not in the fetal HPA axis
G Begum; A Stevens; M Oliver; K Connor; J Challis; F Bloomfield; A White;
16:00 OC1.3 Adipose-specific knockout of androgen receptors in mice results in hyperinsulinaemia without obesity
K McInnes; L Smith; P Saunders; R Andrew; B Walker;
16:15 OC1.4 The impact of saturated fatty acids and glucose on toll like receptor activated inflammatory pathways in human adipose tissue in vitro
A Harte; E Youssef-Elabd; K McGee; G Tripathi; E Ashour; M Aballah; H Sharada; A Amin; A Cariello; P O’Hare; S Kumar; P McTernan;
16:30 OC1.5 The immune-adrenal interface: effects of endotoxin on annexin 1 and formyl peptide receptor expression, cellular morphology and steriodogenesis in the mouse adrenal cortex
N Buss; F Gavins; S Gresham; P Cover; A Terron; J Buckingham;
16:45 OC1.6 Testosterone improves glycemic control, insulin resistance, body fat and sexual function in men with the metabolic syndrome and / or type 2 diabetes – a multicentre European clinical Trial the TIMES2 Study
H Jones; J Howell; K Channer;
17:00 OC1.7 Prospective changes in glucocorticoid metabolism predict alterations in metabolic phenotype
J Tomlinson; J Gray; T McCarthy; S Hughes; B Hughes; P Stewart;
17:15 OC1.8 Cortisol metabolism and hepatic expression of 11B-hydroxysteroid dehydrogenase type 1 in patients with non alcoholic fatty liver disease
A Ahmed; T Brady; C Bailey; P Guest; A Wagenmakers; P Newsome; S Hubscher; E Elisa; D Adams; J Tomlinson; P Stewart;
     
 15:30 17:30    Oral Communications 2
Charter A
15:30 OC2.1 A novel mechanism of effect for somatostatin analogues - the role of AIP
H Chahal; N Alband; O Ansorge; N Karavitaki; E Carlson; J Wass; A Grossman; M Korbonits;
15:45 OC2.2 Wnt/Beta-catenin signalling is down-regulated in pituitary tumours from a Multiple Endocrine Neoplasia Type 1 (MEN1) mouse model
G Walls; P Newey; A Nesbit; J Jeyabalan; H Schultz; N Huebner; R Thakker;
16:00 OC2.3 11C –Metomidate positron emission tomography (PET) scanning for Conn’s Syndrome
T Burton; A Annamalai; N Bird; M Gurnell; M Brown;
16:15 OC2.4 Geographical cluster of familial isolated pituitary adenoma kindreds with an identical AIP mutation
J Cain; Z Ozfirat; H Chahal; K Stals; S Ellard; T Howlett; M Levy; B Atkinson; P Morrison; S Akker; A Grossman; M Korbonits;
16:30 OC2.5 Differential effects of oestrogen on hyhpothalamic GnRH-I and GnRH-II gene expression in female rhesus macaques
H Urbanski; D Eghlidi; S Kohama ;
16:45 OC2.6 Laying the foundation for neuroendocrine control of human reproduction: An investigation into the development of kisspeptin and neurokinin B networks
J Tello; J George; M Milllar; R Anderson; R Millar;
17:00 OC2.7 The spectrum of disease in Diazoxide responsive hyperinsulinaemic hypoglycaemia
M Skae; R Amin; L Patel; H Gleeson; S Ehtisham; M Didi; J Blair; U Das; L Rigby; O Blankenstein; S Ellard; A Kelsey; P Clayton; I Banerjee; C Hall;
17:15 OC2.8 Diagnosis and localisation of insulinoma: the value of modern MRI in conjunction with calcium stimulation catheterisation
V Muthuppalaniappan; M Druce; B O’Leary; S Chew; W Drake; J Monson; S Akker; M Besser; A Sadhev; A Rockall; S Vyas; M Matson; D Berney; S Bhattacharya; A Grossman;
     
 17:30 17:45    Tea & Coffee
     
 17:45 18:45    Young Endocrinologists' Prize Lectures
Exchange Auditorium
Chairs: A McNeily (Edingburgh) & P Trainer (Manchester)
17:45 YEP1 TTG and PBF as targets for augmenting radioiodine uptake in thyroid cancer
V Smith (Birmingham)
18.15 YEP2 RNA interference as therapy for Cushing's disease
A Munir (Sheffield)
     
 19:00     Welcome Reception
Central Hall 1
     
 19:00 21:00    Young Endocrinologists' Quiz Night
Charter 3
     
Tue 16 March
 07:15 08:00    Meet the Expert1 - Glucocorticoid induced osteoporosis
Supported by Clinical Endocrinology
Charter A
Chair: N Gittoes (Birmingham)
R Eastell (Sheffield)
     
 07:15 08:00    Meet the Expert 2 - Funny attacks - flushing, sweating etc
Supported by Clinical Endocrinology
Charter 3
Chair: J Newell-Price (Sheffield)
J Monson (London)
     
 07:15 08:00    Meet the Expert 3 - Metabolomics: challenges and rewards of deciphering the metabolome in diabetes and obesity
Exchange Hall Theatre
Chair: R Andrew (Edinburgh)
 J Griffin (Cambridge)
     
 08:15 10:15    Symposium 3: Stem Cells
Charter 3
Chairs: C Stewart (Manchester) & N Hanley (Manchester)
08:15 S3.1 Hypoxic regulation of hES cells
F Houghton (Southampton)
08:45 S3.2 Pluripotent stem cells in the testis - restoring fertility
S Schlatt (Munster, Germany)
09:15 S3.3 Plasticity of embryonic and adult duct cells
J Ferrer (Barcelona, Spain )
09:45 S3.4 Reprogramming somatic cell identity - a source for replacement therapy
L Vallier (Cambridge)
     
 08:15 10:15    Oral Communications 3
Charter A
Chairs: J Buckingham (London) & A Munir (Sheffield)
08:15 OC3.1 In patients with primary hpyeraldosteronism (PA), careful choice of patients for surgery using a combination of adrenal venous sampling (AVS) data and results of CT scanning, results in excellent post-operative blood pressure and serum potassium responses.
U Graham; K Mullan; S Hunter; H Leslie; P Ellis; B Atkinson;
08:30 OC3.2 Beta-cell specific overexpression of 11beta-hydroxsteroid dehydrogenase Type 1 reverses high fat diet-induced beta-cell failure
S Turban-Rajaonah; X Liu; J Ramage; J Mullins; J Seckl; N Morton;
08:45 OC3.3 Development or urinary steroid profiling as a high-throughput screening tool for the detection of malignancy in patients with adrenal tumours
A Taylor; M Biehl; B Hughes; H Stiekema; P Schneider; D Smith; P Nightingale; C Shackleton; P Stewart; W Arlt;
09:00 OC3.4 MicroRNAs, let-7 an miR-302, have an altered expression in Men1-null embryos, consistent with abnormal embryonic development
M Bowl; P Newey; A Reed; G Walls; D Baban; A Nesbit; R Thakker;
09:15 OC3.5 A multisystem selenoprotein disorder with a thyroid signature
N Schoenmakers; E Schoenmakers; M Agostini; C Mitchell; L Papp; O Rajanayagam; P Padidela; R Doffinger; J Luan; J Lu; I Campi; H Burton; F Muntoni; D O'Donovan; A Dean; A Warren; P Guicheney; R Fitzgerald; M Gurnell; K Chatterjee;
09:30 OC3.6 Men1 gene replacement therapy using a modified adenoviral vector demonstrates reduced proliferation rates in pituitary tumours from mice deleted for a Multiple Endocrine
M Javid; G Walls; M Lemos; J Jeyabalan; M Bazan-Peregrino; D Tyler; D Stuckey; L Seymour; R Thakker;
09:45 OC3.7 Effects of glucocorticoids on Wnt gene expression in synovial fibroblasts: potential role in inflammatory bone loss
R Hardy; P Patel; M Ahasan; E Rabbitt; A Filer; K Raza; C Buckley; P Stewart; M Cooper;
10:00 OC3.8 Identification and functional impact of novel mutations in the gene encoding 11beta-hydroxysteroid dehydrogenase type 1 in patients with hyperandrogenism
A Lawson; E Walker; G Lavery; I Bujalska; B Hughes; W Arlt; J Ride; P Stewart;
     
 08:15 10:15    Clinical Mangement Workshop 2: Endocrine Incidentalomas- What to do with Lumps and Bumps
Supported by Clinical Endocrinology & the Association for Multiple Endocrine Neoplasia Disorders
Exchange Auditorium
Chairs: J Ahlquist (Southend) & A Mukherjee (Salford)
08:15 CM2.1 Thyroid
M Vanderpump (London)
08:45 CM2.2 Pituitary
M Levy (Leicester)
09:15 CM2.3 Adrenal
P Stewart (Birmingham)
09:45 CM2.4 Pancreas
B Harrison (Sheffield )
     
 10:15 10:40    Tea & Coffee
Central Hall 1
     
 10:40 10:45    Update on Cabergoline
Exchange Auditorium
W Drake (London)
     
 10:45 11:25    Society for Endocrinology Dale Medal Lecture
Exchange Auditorium
Chair: J Buckingham (London)
10:45 PL1 Common metabolic disease: Lessons from the extreme
S O'Rahilly (Cambridge)
     
 11:25 11:30    Update on NIHR Funding
Exchange Auditorium
J Wilding (Liverpool)
     
 11:30 12:00    Society for Endocrinology Transatlantic Medal Lecture
Exchange Auditorium
Chair: M Korbonits (London)
11.30 PL2 Pathogenesis of pituitary adenomas
S Melmed (Los Angeles, CA, USA)
     
 12:00 13:30    Lunch & Posters
Central Hall 1
     
 13:30 15:30    Symposium 4: Glucocorticoid Action in Inflammation- New Insights into Old Mechanisms
Exchange Auditorium
Chair: K Chapman (Edinburgh) L Matthews (Manchester)
13:30 S4.1 Tissue-specific glucocorticoid action in inflammation and immunosuppression
J Tuckerman (Jena, Germany)
14:00 S4.2 A novel mechanism of glucocorticoids to block autoimmunity
J Roth (Munster, Germany)
14:30 S4.3 Role of dual specificity phosphatases in biological responses to glucocorticoids
A Clark (London )
15:00 S4.4 Selective glucocorticoid receptor agonists - control of inflammation without metabolic side effects?
H Schacke (Berlin, Germany )
     
 13:30 15:30    Oral Communications 4
Charter A
Chairs: J Compston (Cambridge) & R Ajjan (Leeds)
13:30 OC4.1 Multiple endocrine neoplasia type 1 (MEN-1) mutation analysis in patients with primary hyperparathyroidism
R Mihai; G Sadler; L Walker; R Thakker;
13:45 OC4.2 Intra-cellular availability of T3 in chondrocytes is essential for normal skeletal development and adult bone mass
N Bernstein; M Archanco; R Swinhoe; Y Lu; R Hernandez; D Bassett; G Williams;
14:00 OC4.3 Mice deleted for the transcription factor Gata3 have fewer parathyroid cells expressing Gcm2, develop hypocalcaemia and have an earlier onset of mortality when challenged with a low calcium-vitamin D diet
I Grigorieva; S Mirczuk; K Gaynor; A Nesbit; E Grigorieva; Q Wei; J van der Wees; W Fraser; T Hough; N Manley; F Grosveld; R Thakker;
14:15 OC4.4 Rapid screening for novel bone phenothypes in100 consecutive lines from the Wellcome Trust Sanger Institute Gene Targeting programme
A Gogakos; D Bassett; A van der Spek; H Evans; J White; R Ramirez-Solis; K Steel; A Bradley; R Thakker; P Croucher; G Williams ;
14:30 OC4.5 Dicer-dependent microRNAs regulate IGF-actions in the human placenta
K Forbes; J Aplin; M Westwood;
14:45 OC4.6 Impaired osteoblast function in mice lacking the T3 responsive calcineurin inhibitor RCAN2
D Bassett; A Boyd; P Howell; X Sun; S Xu; Y Murata; G Williams;
15:00 OC4.7 Persistent symptomatic improvement at more than 12 months after parathyroidectomy for primary hyperparathyroidism
R Mihai; P Gopinath; G Sadler;
15:15 OC4.8 Increased mortality in so-called ‘mild’ primary hyperparathyroidism – a population-based study
N Yu; P Donnan; M Murphy; G Leese;
     
 13:30 15:30    Young Endocrinologists' Symposium: Alternative Careers for Basic and Clinical Scientists
Charter 3
Chairs: A Munir (Sheffield) & J George (Glasgow)
13:30 YE1.1 The 'darkside' - pharmaceutical industry for endocrinologists
J Porter (Pfizer)
14:00 YE1.2 Clinical biochemistry - one foot in the lab
S Knox (Glasgow)
14:30 YE1.3 Scientific communication - medical communications agencies
J Nettleship (Agonist Scientific Writing)
15:00 YE1.4 Government agencies - scientific roles in the civil service
N Thatcher (Food Standards Agency)
     
 15:30 16:00    Tea & Coffee
Central Hall 1
     
 16:00 17:00    Clinical Debate: This House Believes that Androgen Replacement Therapy should be offered to every Hypogonadal Woman
Exchange Auditorium
Chair: J Wass (Oxford)
For: S Davies (Australia) Against: S Franks (London)
     
 16:00 18:00    Oral Communications 5
Exchange Hall Theatre
Chairs: S Pearce (Newcastle Upon Tyne) & N Semjonous (Birmingham)
16:00 OC5.1 Familial GC resistance: a novel, naturally occurring mutation which has dominant negative effects on ligand-dependent and independent GR action
P Trebble; L Matthews; J Blaikley; A Wayte; G Black; A Wilton; D Ray;
16:15 OC5.2 De novo cortisol synthesis by primary human keratinocytes
R Hannen; A Michael; J Burrin; M Philpott;
16:30 OC5.3 Differential roles of PAPSS1 and PAPSS2 in the control of androgen synthesis
J McNelis; J Idkowiak; E Nogueira; A Ward; V Dhir; W Arlt;
16:45 OC5.4 Induction of hypothyroidism with radioactive iodine therapy is associated with improved survival in patients with hyperthyroidism
K Boelaert; P Maisonneuve; B Torlinska; J Franklyn;
17:00 OC5.5 Akt activation in a murine thyroid goitre model induced by the tumourigenic factor PBF
M Read; G Lewy; N Sharma; J Fong; V Smith; R Seed; P Kwan; W Leadbetter; A Warfield; J Watkinson; J Franklyn; K Boelaert; C McCabe;
17:15 OC5.6 Is it safe for patients taking thyoxine to have a low but not suppressed serum TSH concentration?
G Leese; R Flynn;
17:30 OC5.7 X Chromosome inactivation: the key to the female preponderance in Graves’ disease?
M Simmonds; P Newby; L Jackson; C Hargreaves; O Brand; J Carr-Smith; J Franklyn; S Gough;
17:45 OC5.8 The effect of genetic variation in PDE8B AND DIO1 on thyroid hormone levels
P Taylor; V Panicker; A Iqbal; N Timpson; J Walsh; C Dayan;
     
 16:00 18:00    Symposium 5: Vitamin D and Calcium Signalling in the Immune System
Charter 3
Chairs: B Fraser (Liverpool) & R Bland (Warwick)
16:00 S5.1 Vitamin D and calcium signalling in autoimmune disease
C Mathieu (Leuven, Belgium)
16:30 S5.2 Anti-bacterial action of vitamin D
M Hewison (Los Angeles, CA, USA)
17:00 S5.3 Vitamin D deficiency increases the risk of multiple sclerosis
B Banwell (Toronto, Canada)
17:30 S5.4 Vitamin D, regulatory T-cells and allergic responses -therapeutic applications
C Hawrylowicz (London)
     
 16:00 17:00    Meet the Expert 1 Repeat: Glucocorticoid induced osteoporosis
Supported by Clinical Endocrinology
Charter A
Chair: N Gittoes (Birmingham)
 R Eastell (Sheffield)
     
 17:00 18:00    Meet the Experts Repeat 2: Funny attacks - flushing, sweating etc
Supported by Clinical Endocrinology
Exchange Auditorium
Chair: J Newell-Price (Sheffield)
 J Monson (London)
     
 17:00 18:00    Meet the Expert 4: Resources in bioinformatics - How can it help your research?
Charter A
Chair: J Connell (Dundee)
 J Watson (Cambridge)
     
 18:00 19:00    Clinical Governance: Interdepartmental Peer Review of Endocrinology Services
Flyer (pdf) (322kb)
Exchange Auditorium
Chair: J Wass (Oxford)
 J Bevan (Aberdeen)
     
 19:30     Conference Dinner
Midland Hotel
     
Wed 17 March
 07:15 08:00    Meet the Experts 5: Acromegaly - Role of primary medical therapy
Supported by Clinical Endocrinology
Exchange Auditorium
Chair: P Trainer (Manchester)
 S Melmed (Los Angeles, CA, USA)
     
 07:15 08:00    Meet the Experts 6: Difficult thyroid function tests
Supported by Clinical Endocrinology
Charter 3
Chair: M Gurnell (Cambridge)
 K Chatterjee (Cambridge)
     
 08:10 08:55    Society for Endocrinology Annual General Meeting
Exchange Auditorium
     
 09:00 11:00    Symposium 6: Fit or Fat? Mechanisms regulating our Metabolic Fate
Exchange Auditorium
Chairs: S O'Rahilly (Cambridge) & S Finer (London)
09:00 S6.1 FTO Polymorphism and food selection in children
C Palmer (Dundee)
09:30 S6.2 The phenotype of the FTO knockout mouse
J Bruning (Cologne, Germany )
10:00 S6.3 Gut-braincircuits controlling glucose homeostasis
T Lam (Toronto, Canada)
10:30 S6.4 Mechanisms of serotonin regulating food intake - the role of the melancortin pathway
L Heisler (Cambridge)
     
 09:00 11:00     Symposium 7: Dilemmas in Managing Gender Identity Problems in Adolescents and Adults
Charter 3
Chairs: P Clayton (Manchester) & L Chan (London)
09:00 Psychological issues
P Cohen-Kettenis (Amsterdam, The Netherlands )
09:30 A medical overview
I Hughes (Cambridge)
10:00 The case for suppressing puberty in adolescent transsexuals
L Gooren (Amsterdam, The Netherlands)
10:30 Managing gender identity problems in adults
L Seal (London )
     
 09:00 11:00    Nurses Session 1: Neuroendocrinology & Case Presentations
Charter A
Chairs: P Yeoh (London) & V Sanderson (Oxford)
09:00 Working together: Genetics and endocrine services
C Gibling (Manchester)
09:40 Case presentation
C Gibson (Manchester)
10:00 UKINETS Speaker
C Bouvier (Warwick) & P Davies (London)
10:40 UKINETS Case presentation
I White (London)
     
 11:00 11:30    Tea & Coffee
Central Hall 1
     
 11:30 12:05    Society for Endocrinology Medal Lecture
Exchange auditorium
Chair: J Buckingham (London)
11.30 PL7 The hitchhiker's guide to the steroid galaxy
W Arlt (Birmingham)
     
 12:05 12:40    Society for Endocrinology Hoffenberg International Medal Lecture
Exchange Auditorium
Chair: G Williams (London)
12.05 PL4 Molecular and endocrine mechanism of seasonal reproduction in birds and mammals
T Yoshimura (Nagoya, Japan)
     
 12:40  14:15    Lunch & Posters
Central Hall 1
     
 14:15 16:15    Symposium 8: Role of Circadian Clock in Endocrinology
Charter 3
Chairs: J Johnston (Guildford) & M Debono (Sheffield)
14:15 S8.1 Molecular basis of the circadian clock - regulation of endocrine rhythms
M Hastings (Cambridge )
14:45 S8.2 Circadian clocks in adipose tissue
J Gimble (Baton Rouge, LA, USA)
15:15 S8.3 The adrenal clock - impact on adrenal steroidogenisis
H Oster (Goettingen, Germany )
15:45 S8.4 Human clock gene polymorphisms and metabolic syndrome
E Scott (Leeds)
     
 14:15 16:15    Clinical Management Workshop 3: Management of Congenital Adrenal Hyperplasia Across the Lifespan
Supported by Clinical Endocrinology
Exchange Auditorium
Chairs: B Allolio (Germany) & N Reisch (Birmingham)
14:15 CM3.1 Prenatal diagnosis and treatment of CAH
A Nordenstrom (Stockholm, Sweden)
14:45 CM3.2 Testicular adrenal rest tissue and male fertility in CAH
H Claahsen-van der Grinten (Nijmegen, The Netherlands )
15:15 CM3.3 The adult with CAH - results of the UK congenital hyperplasia adult study executive (CaHASE)
R Ross (Sheffield )
15:45 CM3.4 Quality of life in CAH - does it differ from adrenal insufficiency?
S Hahner (Wurzburg, Germany )
     
 14:15 16:15    Nurses Session 2: Acromegaly- The overall picture
Supported by the Pituitary Foundation
Charter A
Chairs: M Carson (Edinburgh) & N Kieffer (Leicester)
14:15 Putting acromegaly in perspective
F Swords (Norwich)
15:15 Patients view
S Harris (Birmingham )
15:35 Case presenatation - A Psychological Aspect of Acromegaly
SR Shalet (London )
15:55 Case Presentation - McCune Albrights Syndrome
K Powell (London )
     
 16:15 16:45    Tea & Coffee
Central Hall 1
     
 16:45 17:15    British Thyroid Association Pitt-Rivers Lecture
Exchange auditorium
Chair: J Franklyn (Birmingham)
PL5 Thyroid associations
A Weetman (Sheffield )
     
 17:15 17:45    Clinical Endocrinology Visiting Professor Lecture
Exchange Auditorium
Chair: A Weetman (Sheffield)
PL6 Endocrine hypertension: Then and now
W Young (Rochester, MN, USA)
     
 17:15 17:25   
Exchange Auditorium
Chair: J Franklyn (Birmingham)
 M Cooper (Birmingham)
     
 17:45 18:15    Poster Judging
     
 18:15 20:15    Andrology Special Interest Group Session
Supported by Bayer Shering
Charter A
Chairs: H Jones (Barnsley) & V Vaks (London)
18:15 SIG1.1 Testosterone and all cause mortality
K Khaw (Cambridge )
18:45 SIG1.2 Testosterone defficiency in metabolic syndrome
F Hayes (Dublin, Ireland)
19:15 SIG1.3 Late onset hypogonadism
F Wu (Manchester)
19:45 SIG1.4 Assays problems and treatment decisions - when and how to treat
H Behre (Halle, Germany )
     
 18:15 20:15    Pituitary Special Interest Group Session
Exchange Hall Theatre
Chairs: A Toogood (Birmingham) & F Swords (Norwich)
18:15 SIG2.1 Growth hormone deficiency - a silent epidemic?
M Sherlock (Birmingham)
18:45 SIG2.2 Diagnostic difficulties of growth hormone deficiency
R Murray (Leeds)
19:15 SIG2.3 Therapeutic dilemmas
U Feldt (Copenhagen, Denmark)
19:45 SIG2.4 Future issues for growth hormone replacement in adults
V Popovic (Belgrade, Serbia)
     
 18:15 20:15    Polycystic Ovary Syndrome Special Interest Group Session
Supported by Almiral
Charter 3
Chairs: S Atkin (Hull) & H Randeva (Warwick)
18:15 SIG3.1 Androgen activation by 5alpha-reductase and metabolic effects in PCOS
J Tomlinson (Birmingham)
18:45 SIG3.2 Dermatological aspects of PCOS
A Messenger (Sheffield)
19:15 SIG3.3 Depression and psychosocial aspects in women with PCOS
C Percy (Coventry)
19:45 SIG3.4 Diagnosis and differential diagnosis of PCOS
S Franks (London )
     
 20:15     Free Evening
     
Thur 18 March
 07:55 08:40    Meet the experts 9: The Sanger Institute Mouse Genetics Programme - all you need to know
Exchange Hall Theatre
Chair: J Bruning (Germany)
 J White (Cambridge)
     
 07:55 08:40    Meet the experts 7: Hypocalcaemia & hypomagnesaemia
Charter 3
Chair: S Orme (Leeds)
 N Gittoes (Birmingham)
     
 07:55 08:40    Meet the experts 8: How to run an obesity clinic
Supported by Clinical Endocrinology
Charter 1
Chair: S Aylwin (London)
 J Wilding (Liverpool)
     
 08:50 09:25    Clinical Endocrinology Trust Lecture
Supported by The Clinical Endocrinology Trust
Exchange auditorium
Chair: J Bevan (Aberdeen)
PL8 Ubiquitination - the 'kiss of death' for human growth
P Clayton (Manchester )
     
 09:25 09:45    Awards Ceremony
Exchange auditorium
Chair: J Buckinhgam (London)
     
 09:45 10:00    Tea & Coffee
Central Hall 1
     
 10:00 12:00    Symposium 9: Mechanisms and Management of Ovarian Failure
Charter 3
Chairs: G Conway (London) & H Peltoketo (France)
10:00 S9.11 Genetic mechanisms underlying ovarian insufficiency
K McElreavey (Paris, France )
10:30 S9.2 Mechanisms regulating ovarian reserve
K Hardy (London )
11:00 S9.3 Can ovarian failure be predicted?
F Broekmans (Utrecht, The Netherlands )
11:30 S9.4 Clinical management of ovarian insufficiency
M Davies (London )
     
 10:00 12:00    Clinical Management Workshop 4: The Management of Thyroid Cancer
Supported by Clinical Endocrinology and the British Thyroid Foundation
Exchange auditorium
Chairs: A Allahabadia (Sheffield) & R Mihai (Oxford)
10:00 CM4.1 Investigation of thyroid cancer from lump to surgical referral
P Perros (Newcastle )
10:30 CM4.2 Surgical treatment of thyroid cancer
F Palazzo (London )
11:00 CM4.3 Radio-iodine treatment and long term follow up of differentiated thryoid cancer
F Pacini (Siena, Italy )
11:30 CM4.4 Novel therapies for recurrent thyroid cancer
J Fagin (New York, NY, USA)
     
 10:00 12:30    Senior Endocrinologists' Session
Exchange Hall Theatre
Chairs: D Anderson (Montecastello di Vibio, Italy) & G Vinson (London)
10:00 SE1.1 Will we ever discover the mechanism of hormone action?
TBC
10:25 SE1.2 Sleep, light and hormones in Antartica
J Arendt (Guildford)
10:50 SE1.3 Is the placenta just a parasitic endocrine organ?
P Lowry (Reading)
11:15 SE1.4 Are salivary hormone measurements a waste of time?
P Wood (Southampton)
11:40 SE1.5 Toledo's La Mujer Barbuda; a case report
M Tunbridge (Oxford)
12:05 SE1.6 A second childhood; Walt Disney's politically incorrect movies
H S Jacobs (London)
     
 10:00 12:00    Systems Biology- How to Access Funds and Revolutionise your Research
Charter A
Chairs: J Buckingham (London) & F Gavins (London)
10:00 SB1.1 Systems biology - an overview (BBSRC strategy and funding streams)
C Miles (BBSRC)
10:25 SB1.2 How a mathematician can revolutionise your research
M White (Liverpool)
10:50 SB1.3 Mathmatical modelling and endocrine research
J Davis (Manchester )
11:15 SB1.4 Applications of systems biology for the endocrinologist
A Vidal-Puig (Cambridge)
11:40 SB1.5 Systems biology - a funder's perspective
T Foulkes (MRC)
     
 12:00 12:45    Meet the Experts 5: Acromegaly - role of primary medical therapy
Charter A
Chair: P Trainer (Manchester)
 J Wass (Oxford)
     
 12:00 12:45    Meet the Experts 6 Repeat: Difficult thyroid function tests
Charter 3
Chair: K Chatterjee (Cambridge)
 M Gurnell (Cambridge)
     
 12:45 13:30    Meet the Experts 7 Repeat: Hypocalcaemia & Hypomagnesaemia
Charter A
Chair: S Orme (Leeds)
 N Gittoes (Birmingham)
     
 12:45 13:30    Meet the Experts 8 Repeat: How to run an obesity service
Charter 3
Chair: S Aylwin (London)
 J WIlding (Liverpool)